Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy

TETSUYA SHINDO; KOHEI HASHIMOTO; ATSUSHI TAKAHASHI; SHINTARO MIYAMOTO; YASUHARU KUNISHIMA; SHUNSUKE SATO; FUMIMASA FUKUTA; YOSHIKI HIYAMA; AKIO TAKAYANAGI; RYUICHI KATO; ATSUSHI WANIFUCHI; YOHEI UEKI; MANABU OKADA; HIDEKI ADACHI; KO KOBAYASHI; TOSHIAKI TANAKA; NAOYA MASUMORI

doi:10.21873/anticanres.16922

Research ArticleClinical Studies

Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy

TETSUYA SHINDO, KOHEI HASHIMOTO, ATSUSHI TAKAHASHI, SHINTARO MIYAMOTO, YASUHARU KUNISHIMA, SHUNSUKE SATO, FUMIMASA FUKUTA, YOSHIKI HIYAMA, AKIO TAKAYANAGI, RYUICHI KATO, ATSUSHI WANIFUCHI, YOHEI UEKI, MANABU OKADA, HIDEKI ADACHI, KO KOBAYASHI, TOSHIAKI TANAKA and NAOYA MASUMORI; on behalf of the Sapporo Medical University Urologic Oncology Consortium

Anticancer Research March 2024, 44 (3) 1271-1279; DOI: https://doi.org/10.21873/anticanres.16922

TETSUYA SHINDO

1Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: shindo1013{at}yahoo.co.jp

KOHEI HASHIMOTO

1Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

ATSUSHI TAKAHASHI

2Department of Urology, Hakodate Goryoukaku Hospital, Hakodate, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

SHINTARO MIYAMOTO

3Department of Urology, Japanese Red Cross Asahikawa Hospital, Asahikawa, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

YASUHARU KUNISHIMA

4Department of Urology, Sunagawa City Medical Center, Sunagawa, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

SHUNSUKE SATO

5Department of Urology, Oji General Hospital, Tomakomai, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

FUMIMASA FUKUTA

6Department of Urology, Steel Memorial Muroran Hospital, Muroran, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

YOSHIKI HIYAMA

7Department of Urology, NTT Medical Center Sapporo, Sapporo, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

AKIO TAKAYANAGI

8Department of Urology, Japan Community Healthcare Organization Hokkaido Hospital, Sapporo, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

RYUICHI KATO

9Department of Urology, Muroran City General Hospital, Muroran, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

ATSUSHI WANIFUCHI

10Department of Urology, Japanese Red Cross Kushiro Hospital, Kushiro, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

YOHEI UEKI

11Department of Urology, Takikawa Municipal Hospital, Takikawa, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

MANABU OKADA

12Department of Urology, Obihiro Kyokai Hospital, Obihiro, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

HIDEKI ADACHI

13Department of Urology, Saiseikai Otaru Hospital, Otaru, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

KO KOBAYASHI

1Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

TOSHIAKI TANAKA

1Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

NAOYA MASUMORI

1Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
PDF

Log in using your username and password

Username *

Password *

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles

PreviousNext

In this issue

Anticancer Research

Vol. 44, Issue 3

March 2024

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Back Matter (PDF)
Ed Board (PDF)
Front Matter (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy

Message Subject (Your Name) has sent you a message from Anticancer Research

Message Body (Your Name) thought you would like to see the Anticancer Research web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Math question * 16 + 1 =

Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

Citation Tools

Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy

Anticancer Research Mar 2024, 44 (3) 1271-1279; DOI: 10.21873/anticanres.16922

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Reprints and Permissions

Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy

Anticancer Research Mar 2024, 44 (3) 1271-1279; DOI: 10.21873/anticanres.16922

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Figures & Data
Info & Metrics
PDF

Cited By...

Survival and Safety Outcomes of Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma from a Single-Center Experience
Efficacy of Pembrolizumab as Second or Third-line Therapy for Local Advanced and Metastatic Urothelial Cancer
Treatment Outcomes After Progression With Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma
Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab Versus Pembrolizumab Therapy
Optimal Number of Cycles of First-line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma

Google Scholar

Keywords

Advanced urothelial carcinoma
pembrolizumab
avelumab
propensity score match

Main menu

User menu

Search

Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy

Purchase access

patientACCESS

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Keywords